Modeling Human Cancer in Mice 40x 10x · Modeling Human Cancer in Mice Xenograft Models Xenograft...

56
Modeling Human Cancer in Mice 40x 10x Presented by: Brian W. Soper, PhD Technical Information Services Hosted by Charles River, exclusive distributor of JAX ® Mice in 27 European Countries

Transcript of Modeling Human Cancer in Mice 40x 10x · Modeling Human Cancer in Mice Xenograft Models Xenograft...

Modeling Human

Cancer in Mice 40x

10x

Presented by:

Brian W. Soper, PhD

Technical Information Services

Hosted by Charles River, exclusive

distributor of JAX® Mice in 27 European

Countries

The Jackson Laboratory’s Mission

2

Performing Research

Investigating genetics and biology of human disease

Providing Resources

JAX® Mice Clinical & Research Services, bioinformatics data,

technical publications and more…

Educating Scientists

World-class courses, internships and other programs

www.jax.org/courses |

JAX® Mice The Gold Standard for Biomedical Research

JAX® Mice The Gold Standard for Biomedical Research

3

NIH funded resource

>7,000 strains and growing

o 2.7 million mice shipped annually

Unsurpassed genetic quality & animal health

Best characterized & referenced ~100 new pubs/week

Common inbred strains (C57BL/6J, BALB/cJ, DBA/2J) support

development/collection of specialty strains and other valuable

community research resources

JAX® Mice |

Online Resources to Expedite

Research

4

JAX® Mice Database

www.jax.org/jaxmice

www.jax.org/jaxmice/support/techsupport-index |

Online Resources to Expedite

Research

5

JAX® Mice Database

www.jax.org/jaxmice

Mouse Genome Informatics

www.informatics.jax.org

www.jax.org/jaxmice/support/techsupport-index |

Online Resources to Expedite

Research

6

JAX® Mice Database

www.jax.org/jaxmice

Mouse Genome Informatics

www.informatics.jax.org

Mouse Phenome Database

www.jax.org/phenome

And many more unique

resources

www.jax.org/jaxmice/support/techsupport-index |

Modeling Human Cancer in Mice

Xenograft Models

Xenograft Host Selection

Spontaneous and Inducible Models

Online Data and Resources

JAX® Mice | 8

Utilizing Xenograft Models

Xenograft Sample

o Established cell lines

o Primary cell lines

o Patient derived tumor tissue

Immunodeficient Hosts

o Nude

o NOD-scid

o NOD-scid gamma (NSG)

JAX® Mice | 9

Utilizing Xenograft Models

Xenograft Sample

o Established cell lines

o Primary cell lines

o Patient derived tumor tissue

Immunodeficient Hosts

o Nude

o scid

o NOD-scid gamma (NSG)

JAX® Mice | 10

Inbred and Outbred Nude Mice

Mouse Nomenclature

Inbred Nude NU/J (002019)

Outbred Nude J:NU (007850)

Immunological Deficiencies

Mutation: Foxn1nu

Athymic and T cell Deficient

Flanagan SP. 1966. Genet Res 8(3):295-309. PMID:5980117

Pantelouris EM. 1973. Differentiation 1(6):437-50. PMID:4547146

JAX® Mice | 13

Inbred and Outbred Nude Mice

Mouse Nomenclature

Inbred Nude NU/J (002019)

Outbred Nude J:NU (007850)

Immunological Deficiencies

Mutation: Foxn1nu

Athymic and T cell Deficient

Applications and Benefits

Engraftment of human & mouse tumor cell lines

Well published/characterized

Hairless phenotype enhances assessment of tumor growth

Flanagan SP. 1966. Genet Res 8(3):295-309. PMID:5980117

Pantelouris EM. 1973. Differentiation 1(6):437-50. PMID:4547146

JAX® Mice | 14

Easy Evaluation of Therapeutic

Response in Nude Mice

Gulliya KS et al. 1994. Cancer 74(6):1725-32. PMID:8082074

Before treatment After treatment

JAX® Mice | 16

Nude Mice

Mouse Nomenclature

Inbred Nude NU/J (002019)

Outbred Nude J:NU (007850)

Immunological Deficiencies

Mutation: Foxn1nu

Athymic and T cell deficient

Considerations

Innate immunity intact

Not useful for hematopoietic cancer models

Not suitable for primary cell transplantation

Flanagan SP. 1966. Genet Res 8(3):295-309. PMID:5980117

Pantelouris EM. 1973. Differentiation 1(6):437-50. PMID:4547146

17 JAX® Mice |

BALB/c-scid

Mouse Nomenclature

CBySmn.CB17-Prkdcscid/J (001803)

o Similar to original C.B-17 scid

Immunological Deficiencies

Mutation: scid “severe combined immune deficiency”

No mature B and T cells

JAX® Mice | 18

BALB/c-scid

Mouse Nomenclature

CBySmn.CB17-Prkdcscid/J (001803)

o Similar to original C.B-17 scid

Immunological Deficiencies

Mutation: scid “severe combined immune deficiency”

No mature B and T cells

Applications

Xenograft host for cancer cell lines

Efficacy testing of therapeutic antibodies (CDC and ADCC intact)

Adoptive transfer from BALB/c donors

Infectious disease

Common inbred background simplifies creation of compound

immunodeficient mutants

JAX® Mice | 19

BALB/c-scid

Therapeutic Ab/Fusion Protein Efficacy

Shin S et al. 2011. Mol Cancer Ther 10:603-614. PMID:21393427

JAX® Mice | 21

Human SK-BR-3 Breast Cancer Cells

Mouse Nomenclature CBySmn.CB17-Prkdcscid/J (001803) o Similar to original C.B-17 scid

Applications Xenograft host for cancer cell lines

Efficacy testing of therapeutic antibodies

Adoptive transfer from BALB/c donors

Common inbred background simplifies creation of compound immunodeficient mutants

Considerations Innate immunity intact

scid side effects: radiation sensitivity; genotoxic drugs may have higher toxicity

High scid leakiness; mice develop T and B cells as they age

BALB/c-scid

JAX® Mice | 22

NOD-scid

Mouse Nomenclature NOD.CB17-Prkdcscid/J (001303)

Immunological Deficiencies Mutation: scid “severe combined immune deficiency”

No mature B and T cells

Reduced innate immunity o macrophage, dendritic, and NK cell deficits

o complement deficient

o Sirpα allele

Applications Xenotransplantation of human tumors

Engrafts some hematopoietic cancer cell lines

Adoptive transfer recipient for study of autoimmune type 1 diabetes

Significantly less scid leakiness than other backgrounds

Shultz LD et al. 1995. J Immunol 154(1):180-91.PMID:7995938

Banuelos SJ et al. 2004. Clin Immunol 112(3):273-83. PMID:15308121

JAX® Mice | 23

NOD-scid Mice Propagate

Medulloblastoma-like Tumors

Werbowetski-Ogilvie TE et al. 2012. Stem Cells 30(3):392-404 PMID:22213600

JAX® Mice | 26

Arrows point to

neural rosettes

NOD-scid

Mouse Nomenclature

NOD.CB17-Prkdcscid/J (001303)

Immunological Deficiencies

Mutation: scid “severe combined immune deficiency”

No mature B and T cells

Reduced innate immunity

Considerations

Short life span (thymic lymphoma by ~9 months

Residual innate immunity (NK cell function)

scid side effects: radiation sensitivity; genotoxic drugs may have

higher toxicity Shultz LD et al. 1995. J Immunol 154(1):180-91. PMID:7995938

Banuelos SJ et al. 2004. Clin Immunol 112(3):273-83. PMID:15308121

JAX® Mice | 27

NSG, NOD scid gamma

Mouse Nomenclature

NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (005557)

Immunological Deficiencies

NOD background contributes innate immune deficiencies

o Absence of hemolytic complement

o Reduced dendritic cell function

o Defective macrophages

o Sirpα allele

scid mutation prevents maturation of T and B cells

Il2rg deficiency eliminates signaling from 6 distinct interleukins

and blocks NK cell development

JAX® Mice | 28

NSG, NOD scid gamma Mouse Nomenclature

NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (005557)

Immunological Deficiencies

NOD background contributes innate immune deficiencies

o Absence of hemolytic complement

o Reduced dendritic cell function

o Defective macrophages

o Sirpα allele

scid mutation prevents maturation of T and B cells

Il2rg deficiency eliminates signaling from 6 distinct interleukins

and blocks NK cell development

Benefits No scid-associated leakiness Longer life span than NOD-scid (> 16 months) Enhanced human hematopoietic stem cell engraftment (Sirpa allele)

JAX® Mice | 29

NSG, NOD scid gamma Mouse Nomenclature

NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (005557)

Immunological Deficiencies

NOD background contributes innate immune deficiencies

scid mutation prevents development of mature T and B cells

Il2rg deficiency eliminates signaling from 6 distinct interleukins

and blocks NK cell development

Benefits

Optimal human hematopoietic stem cell engraftment (Sirpa allele)

No scid-associated leakiness

Longer life span than NOD-scid (> 16 months)

Limitations/Considerations

scid side effects: radiation sensitivity; genotoxic drugs may have

higher toxicity

JAX® Mice | 31

NSG: Improved Melanoma

Metastasis Model

Carreno et al. 2008. Clin Cancer Res 15(10):3277-86. PMID:19447870

Cell line:

o A375 human malignant melanoma

o Luciferase tagged

o Injected I.V.

JAX® Mice | 32

NSG

C.B-17

scid

H&E Human cells

(anti-HLA)

Mouse blood cells

(anti-mCD45)

H&E

Cancer

Patient’s Lung

Tumor

Fragment

NSG Mice Preserve Patient Tumor

Characteristics

Simpson-Abelson MR et al. 2008.J Immunol 180(10):7009-18. PMID:18453623

JAX® Mice | 33

Pati

en

t tu

mo

r E

ng

raft

ed

tum

or

H&E Cytokeratin Ki67 Simpson-Abelson MR et al. 2008.J Immunol 180(10):7009-18. PMID:18453623

JAX® Mice | 34

NSG Mice Preserve Patient Tumor

Characteristics

JAX Patient-Derived Xenograft

(PDX) Program

In Vivo Pharmacology Services |

Collect primary human patient samples and engraft into NSG mice

Model Supporting Data

Clinical information:

o Tumor type, grade and markers (if known)

o treatment history

Histology

Gene expression array data

CNV array analysis

35

Access supporting data at

www.tumor.informatics.jax.org/mtbwi/pdxSearch.do

Estrogen Receptor Positive

Breast Carcinoma

NSG supports growth of ER+ breast tumors in combination with estrogen pellets

Tumors retain “organoid” growth pattern

TM00386 PT TM00386-294 P0

PT= Patient Tumor; P0 = first patient derived xenograft (PDX) generation in mouse;

P1 = 2nd generation

TM00386-294 P1

TM00386 (ER+/PR+/Her2-)

In Vivo Pharmacology Services | 37

Spontaneous and Induced Models

Prominent and Newly Emerging Models

Breast Cancer

Lung Cancer

Prostate Cancer

Intestinal/Colon Cancer

Melanoma

Pancreatic Cancer

JAX® Mice | 38

Mammary Cancer Model FVB/N-Tg(MMTV-PyVT)634Mul/J (002374)

B6.FVB-Tg(MMTV-PyVT)634Mul/LellJ (022974)

Guy CT et al. 1992. Mol Cell Biol 12(3):954-61. PMID:1312220

Lifsted T et al. 1998. Int J Cancer 77(4):640-4. PMID:9679770

Davie SA et al. 2007 Transgenic Res 16(2):193-201. PMID: 17206489

JAX® Mice | 39

FVB/N Characteristics:

100% incidence

o Females: median age 53 days

o Pregnancy accelerates

tumorigenesis

Metastasize to the lung

o 80-94% of females

B6 Characteristics:

100% incidence

o Females: median age 92 days

Metastasize to the lung

o Reduced compared to FVB/N

background

Mammary Cancer Model STOCK Trp53tm1Brd Brca1tm1Aash Tg(LGB-cre)74Acl/J

(012620)

Characteristics:

Trp53 -/+, floxed Brca1, Lactoglobulin β-cre

64% of mice develop mammary gland tumors

o Human basal-like breast cancer

o High grade DCIS adjacent to invasive tumor

o Metaplastic element

Two rounds of breeding required

o Hormone accelerated phenotype

o Tumor development by 31 weeks

McCarthy A. TV et al. 2007. J Path 211(4):389-98. PMID:17212342

40 JAX® Mice |

High Grade Invasive

Ductal Carcinoma

Nuclear

Pleomorphism

Early-Stage Lung Cancer Model B6.129S4-Krastm4Tyj/J (008179)

Characteristics:

Floxed-stop mutant oncogenic

KrasG12D

Cre introduced nasally

(Adeno-cre)

Lesions induced 6 weeks post-cre

administration

Adenocarcinomas by 16 weeks

post-cre administration

Progressive lung disease: atypical adenomatous

hyperplasia to adenoma

Jackson EL et al. 2001. Genes Dev 15(24):3243-8. PMID: 11751630.

Meylan E et al. 2009. Nature 462(7269):104-7. PMID: 19847165.

5x105 pfu @ 6wks 5x106 pfu @ 6wks

Prostate Cancer Models TRAMP strains

Greenberg NM et al. 1995. PNAS 92(8):3439-43. PMID:7724580 Gingrich JR et al. 1996. Cancer Res 56(18):4096-102. PMID:8797572

Albertelli et al. 2006. Mol Endocrinol 20(6):1248-60. PMID:16601069

TRansgenic Adenocarcinoma Mouse Prostate

C57BL/6-Tg(TRAMP)824Ng/J (003135)

(C57BL/6-Tg(TRAMP)8247Ng/J X FVB/NJ)F1/J (008215)

Characteristics: o Background influences tumor

development

o F1 shorter lifespan

F1 ~19 wks

B6 ~52 wks

o 100% metastatic in F1

Neuroendocrine cells

Lungs or lymph nodes

About 28 weeks of age

o SV40 Tumor-antigen

o Variable tumor latency

Hyperplasia

(~10 weeks)

Adenocarcinoma

(~18wks)

JAX® Mice | 42

Inducible Prostate Cancer Models FVB;B6-Tg(Pbsn-cre)20Fwan/J (023325)

43

Publication involving:

B6.129S4-Krastm4Tyj/J (008179)

Scrib loxp-flanked mice

Probasin cre (Pbsn-cre) alone does not develop tumors

Pbsn-cre::KrasG12D/+::Scribfl/fl generates invasive carcinoma (~400 days)

Pearson HB et al. 2011. J Clin Invest 121(11):4257-67. PMID: 21965329

PIN = prostate intraepithelial neoplasia

Intestinal / Colon Cancer Model C57BL/6J-ApcMin/J (002020)

Adenomatosis Polyposis Coli, Multiple Intestinal Neoplasia

Characteristics:

Adenomas to adenocarcinomas

o Spontaneous, 100% incidence

o Age of onset: 2.6–8.7 months

o Higher polyp count on high fat diet

Females unhealthy

o Severely anemic & die by 4 months

o 12% mammary tumor incidence

Homozygous lethal e7.0 Moser AR et al. 1990. Science 247:322-4. PMID:2296722

Su LK et al. 1992. Science 256:1114. PMID:1350108

Normal intestinal tract

Multiple Adenomas

(131 days)

JAX® Mice | 44

Melanoma Model STOCK Braftm1Mmcm Ptentm1Hwu

Tg(Tyr-cre/ERT2)13Bos/BosJ (013590)

Dankort et al. 2009. Nature Genetics 41(5):544-52. PMID:19282848

Damsky et al. 2011. Cancer Cell 20(6):741-54. PMID:22172720

45 JAX® Mice |

Floxed conversion to BrafV600E

Floxed Pten KO

Inducible melanomas in 3-4 weeks

25% spontaneous melanomas in 2-12 mo.

Skin

Lung

Pancreatic Cancer Modeling B6.FVB-Tg(Pdx1-cre)6Tuv/J (014647)

Hill et al. 2010. Cancer Res 10(18):7114-24. PMID:20807812

Triple compound mutant mice develop

pancreatic ductal adenocarcinoma

Recent publication involving:

C;129S4-Ptentm1Hwu/J (004597)

B6.129S4-Krastm4Tyj/J (008179)

JAX® Mice | 46

Pdx1 promoter; pancreatic and duodenal homeobox 1

Additional Models Available

www.jax.org/jaxmice/cancer/index.html

47

MTB Web Interface

Search for Mammary gland

adenocarcinomas with

metastases to the lung &

pathology images available

JAX® Mice | 51

MTB Mammary Adenocarcinomas

with Metastases to Lungs + Images

JAX® Mice | 52

Mammary Gland Images for

FVB/N-Tg(MMTVneu)202Mul/J

JAX® Mice | 53

PDX Models Search

55 JAX® Mice | tumor.informatics.jax.org/mtbwi/pdxSearch.do

Primary tumor site

Diagnosis

Gene Variants

Gene Expression Chart

Gene Amplification/Deletion (CNVs)

56

Charles River is the

Exclusive Distributor of

JAX® Mice in 27

European Countries*

Contact Charles River:

[email protected]

*Albania, Austria, Belgium, Bosnia-

Herzegovina, Bulgaria, Croatia, Czech

Republic, Denmark, Finland, France,

Germany, Hungary, Ireland, Italy,

Luxembourg, Macedonia, Montenegro,

Netherlands, Norway, Poland, Portugal,

Serbia, Slovenia, Spain, Switzerland, Sweden,

and the United Kingdom

Thank you!

JAX® Mice, Clinical &

Research Services

www.jax.org